Cell-type specific expression in the pituitary: physiology and gene therapy

Castro, María G.; Windeatt, S.; Smith-Arica, Joseph R.; Löwenstein, Pedro R.

doi:10.1042/bst0270858

Cited by 19 publications

(7 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This colloquium also continues several articles on the application of gene therapy to specific tissue targets, including the pituitary [18], the cardiovascular system [19] and the brain [20]. Also discussed are specific therapeutic targets such as heart allgraft transplantation [19], brain tumours [20] and autoimmune disease [21].…”

Section: Biochemical Society Transactionsmentioning

confidence: 84%

Recent articles of interest to biotechnology in other Portland Press journals

Lundblad

2000

Biotech and App Biochem

View full text Add to dashboard Cite

Section: Biochemical Society Transactionsmentioning

confidence: 84%

Recent articles of interest to biotechnology in other Portland Press journals

Lundblad

2000

Biotech and App Biochem

View full text Add to dashboard Cite

“…In addition to cell-type-speci®c expression of the therapeutic gene, regulation of transgene expression is foreseeable for gene therapy of many endocrine disorders. The tetracycline-inducible system, which allows gene expression to be regulated by the tetracycline analogue doxycycline, has been used to develop a PRL-speci®c and regulatable adenoviral vector (188,189). By driving the expression of the tetracycline transactivator through the PRL-speci®c promoter, expression of the inducible transgene was restricted to both lactotrophic tumour cell lines and PRL-positive cells in primary anterior pituitary cultures (188,189).…”

Section: Endocrine Tumoursmentioning

confidence: 99%

New perspectives for gene therapy in endocrinology

Barzon

Bonaguro²,

Palù³

et al. 2000

European Journal of Endocrinology

View full text Add to dashboard Cite

Gene therapy for endocrine diseases represents an exciting new type of molecular intervention that may be a curative one. Endocrine disorders that might be treated by gene therapy include monogenic diseases, such as GH deficiency and hypothalamic diabetes insipidus, and multifactorial diseases, such as diabetes mellitus, obesity and cancer. Premises seem promising for endocrine tumours, but many combined approaches of cell and gene therapy are foreseeable also for other endocrine disorders. This review outlines the principles of gene therapy, describes the endocrine disorders that might take advantage of gene transfer approaches, as well as the gene therapy interventions that have already been attempted, their major limitations and the problems that remain to be solved.

show abstract

“…Interestingly, recombinant adenoviral vectors have been successfully used for gene transfer into the anterior pituitary gland both in vitro 77–79 and in vivo 80. Adenoviral vectors have been employed to transduce pituitary adenoma cell lines and animal models with the HSV thymidine kinase product 81.…”

Section: Gene Delivery Into Endocrine Tissues: New Perspectives For Tmentioning

confidence: 99%

“…Adenoviral vectors have been employed to transduce pituitary adenoma cell lines and animal models with the HSV thymidine kinase product 81. Cell‐type specific adenoviral‐mediated transgene expression was achieved in the pituitary gland using the GH gene promoter 77,78. Recombinant retroviruses were tested on the AtT20 pituitary cell line,82,83 but the efficiency of transduction was low.…”

Section: Gene Delivery Into Endocrine Tissues: New Perspectives For Tmentioning

confidence: 99%

Genomic Medicine

Alesci¹,

Chrousos²,

Pacák³

2002

Annals of the New York Academy of Sciences

View full text Add to dashboard Cite

Recent improvements in defining the molecular basis of disease have encouraged scientists worldwide to develop new therapeutic strategies based on engineered genes and cells. Genomic medicine has the potential to revolutionize diagnosis and therapy of a variety of human diseases, including endocrine disorders. Hypertension is the presenting feature of some of these disorders, such as congenital adrenal diseases, and adrenal and pituitary tumors. Preclinical data indicate that gene transfer to both the adrenal gland and the pituitary is not only feasible but also quite efficient. Research in this field is only in its infancy, but with the ever-increasing advances in DNA technologies, genomic therapies for endocrine hypertension may become available within the next few decades.

show abstract

Cell-type specific expression in the pituitary: physiology and gene therapy

Cited by 19 publications

References 9 publications

Recent articles of interest to biotechnology in other Portland Press journals

Recent articles of interest to biotechnology in other Portland Press journals

New perspectives for gene therapy in endocrinology

Genomic Medicine

Contact Info

Product

Resources

About